Liraglutide Liraglutide (Victoza) was approved for use in T2D in 2009 by the EMA at doses of up to 1.8 mg once daily subcutaneous injection for people with T2D as monotherapy in those unable to take metformin or as add-on treatment to oral agents and/or insulin
Although initial reports localised OCT1 to the basolateral membrane [19], more recent reports place OCT1 on the apical surface of intestinal epithelial cells [20, 21]
Kwack MH, Ahn JS, Kim MK, Kim JC, Sung YK (2012) Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice
Given these practical constraints, clinicians, formulary decision-makers, and payers should use a patient-centered approach, balancing efficacy, costs, patient preferences, and safety considerations when selecting obesity pharmacotherapy
Why Cora Healths pricing is different Cora Health uses an all-inclusive pricing model